Danaher beats Q1 earnings estimates but misses revenue due to weak respiratory season.

Danaher Corporation reported Q1 adjusted earnings per share of $2.06, beating analyst estimates of $1.94, but its revenue of $5.95 billion fell short of the expected $5.99 billion. The revenue miss was mainly due to a weaker respiratory season affecting its Cepheid business, despite strong results in Bioprocessing and Life Sciences. For Q2, Danaher expects low-single-digit core revenue growth and raised its full-year adjusted EPS guidance to $8.35-$8.55, above analyst expectations. This shows resilience amid some sector challenges and a positive outlook for the year ahead.